Clinical trial
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck…
NCT00337129 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00337129 |
|---|---|
| Title | S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
| Official title | Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | eribulin mesylate |
| Enrollment | 42 |
| Start date | May 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Jul 1, 2011 |
| First posted | Jun 15, 2006 |
| Last update posted | Aug 25, 2015 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: